Gujarat Kidney and Super Speciality PE ratio history and valuation
NSE: GKSLBSE: 544666Healthcare ServicesSmall Cap
Gujarat Kidney and Super Speciality Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 2025 · Issue price ₹114
Last close ₹163.31down ₹8.56 (4.98%)BSE ₹163.50
Share price at the NSE close on 30 Oct 2026. Previous close ₹171.87.
30 Oct: open ₹171.90, high ₹172.58, low ₹160.84
Range of traded prices from listing on 30 Dec 2025 to 30 Oct 2026
₹98.36Low, 23 Jan 2026₹209.80High, 1 Oct 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,288 Cr1,531st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 5.10
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonesince listing in Dec 2025
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 8.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.06
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 8,79,68846.6% delivered
Gujarat Kidney and Super Speciality's price to book, price to sales, EV to EBITDA and dividend yield on 30 Oct 2026, each against its own history of up to a year. Its P/E is not shown: the figures it needs for the twelve months to Jun 2026 are not complete or not comparable.
Gujarat Kidney and Super Speciality PE ratio and valuation against its own history
- Price to earningsA results filing in the last twelve months restated the quarters before it inside its year to date, so the four quarters as the company reported them do not add to a twelve-month profit; the ratio returns once the trailing year no longer holds a quarter from before the restatement
- Price to book5.10today
- Price to salesPrice to sales, trailing. Market cap divided by the revenue of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what investors pay for each rupee of a year's sales.12.74today
- EV to EBITDAEnterprise value to EBITDA. Market cap plus borrowings less cash and bank balances, divided by operating profit before depreciation (revenue less operating expenses, without other income and one-off items) over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what the whole business costs against the profit its operations make. Lease liabilities are not counted: the results filings do not state them.46.72today
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.0.00%today
1 year, since Dec 2025
Median 0.00%Today is at or above 100% of the 207 days
- Earnings yieldEarnings yield. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) as a percentage of market cap, the P/E turned upside down.A results filing in the last twelve months restated the quarters before it inside its year to date, so the four quarters as the company reported them do not add to a twelve-month profit; the ratio returns once the trailing year no longer holds a quarter from before the restatement
Each track ranks every trading day in the window from the day the ratio was lowest to the day it was highest; the dot is today. The share under it is how many of those days the ratio was at or below today's level, so a high share means today is higher than on most days in the window. A window is shown only when the ratio is held on most of its trading days; a day after a loss-making year has no P/E. Dividend yield is in per cent. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
How each ratio is worked out, with today's figures
- Price to book =Market cap÷Net worthNet worth. Shareholders' equity in the latest balance sheet. Net worth in the glossary₹253 Cr
- Price to sales =Market cap÷Revenue, last twelve monthsRevenue, last twelve months. Revenue from operations over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly).₹101 Cr
- Enterprise value =Market cap+BorrowingsBorrowings. Total borrowings in the latest balance sheet. Borrowings in the glossary₹16 Cr−CashCash. Cash and bank balances in the latest balance sheet.₹56 Cr
- EV to EBITDA =Enterprise value÷Operating profit, last twelve monthsOperating profit, last twelve months. Profit before depreciation, interest and tax over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly).₹27 Cr
- Market cap =Close×Shares in issueShares in issue. The shares in issue in the latest shareholding filing.7,88,43,250at 30 Sep 2026
Consolidated accounts, the twelve months to Jun 2026, balance sheet at Mar 2026, ₹ crore.Gujarat Kidney and Super Speciality financials ›
Gujarat Kidney and Super Speciality valuation at each year end
On the last trading day of each March, the month the company's year ends.
| Ratio | Mar 2026 |
|---|---|
| Market cap (₹ crore)Market capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. | 799 |
| Price to earnings | No full year |
| Price to book | No balance sheet |
| Price to sales | No full year |
| EV to EBITDA | No full year |
| Dividend yield | 0.00% |
| Earnings yield | No full year |
A ratio that does not exist on the day says why in its cell.
Gujarat Kidney and Super Speciality market cap, since Dec 2025
The last trading day of each month.
Market cap, ₹ crore
- Market cap
Book value and enterprise value
From the close on 30 Oct 2026.
- Enterprise valueEnterprise value. Market cap plus borrowings less cash and bank balances: what it would cost to buy the whole business, its debts included.
- ₹1,247 Cr
- Book value per shareBook value per share. Net worth, the company's assets less everything it owes, divided by the number of shares in issue.
- ₹32.03
- Dividends, last 12 monthsDividends per share, last 12 months. Dividends per share with an ex-date in the last twelve months, restated for any split or bonus since.
- None
- Public's market capPublic's market cap. The market value of the shares held by everyone other than the promoters, the group that set up or controls the company.
- ₹368 Cr
Against Hospital
40 listed companies in Hospital, each priced on its last trading day; Gujarat Kidney and Super Speciality is 22nd among them by market cap. Each median leaves out Gujarat Kidney and Super Speciality itself and takes the other companies that have the figure.
- Industry median P/EIndustry median trailing P/E. The middle trailing P/E of the listed companies in the same industry that have one, leaving out the company itself and any P/E above 200.
- 42.2Across 26 other companies
- Industry median P/BIndustry median P/B. The middle P/B of the listed companies in the same industry that have one, leaving out the company itself.
- 4.4Across 32 other companies
- Industry median EV/EBITDAIndustry median EV/EBITDA. The middle EV/EBITDA of the listed companies in the same industry that have one, leaving out the company itself.
- 22.3Across 21 other companies
- Industry median dividend yieldIndustry median dividend yield. The middle dividend yield of the listed companies in the same industry that paid a dividend in the last twelve months, leaving out the company itself.
- 0.24%Across 15 other companies
| Company | |||||
|---|---|---|---|---|---|
 Indraprastha Medical CorporationINDRAMEDCO | 2,802 | 14.58 | 3.44 | 9.3 | 1.31% |
 Dr Agarwals Eye HospitalDRAGARWQ | 2,570 | 33.72 | 7.42 | 17.5 | 0.13% |
 K M C Speciality Hospitals (India)KMCSHIL | 2,420 | 43.39 | 11.50 | 24.4 | 0.00% |
 ShalbySHALBY | 1,303 | 33.15 | 1.30 | 12.7 | 0.00% |
| Gujarat Kidney and Super SpecialityGKSL | 1,288 | – | 5.10 | 46.7 | 0.00% |
 GPT HealthcareGPTHEALTH | 1,089 | 23.03 | 4.04 | 12.1 | 1.88% |
 Unihealth HospitalsUNIHEALTH | 944 | 36.53 | – | – | 0.00% |
 Rays of BeliefMOMSBELIEF | 512 | – | – | – | 0.00% |
 Asarfi HospitalASARFI | 314 | 18.83 | 3.21 | – | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.